Nanotheranostics 2023; 7(1):102-116. doi:10.7150/ntno.76559 This issue Cite

Research Paper

Development of a Personalised Device for Systemic Magnetic Drug Targeting to Brain Tumours

Priya Patel1*, Areej Alghamdi1*, Gary Shaw2, Christopher Legge3, Maggie Glover1, Danielle Freeman1, Harry Hodgetts1, Erica Wilson2, Faith Howard1, Sarah Staniland3, Aneurin J Kennerley4, Duncan Wood1, Robert Moorehead1, Charlotte Hadfield1, Ola Rominiyi1, Jon Griffin1, Spencer J Collis1, Sam Hyde5, Marcus Crossley5, Martyn Paley1, Munitta Muthana1✉

1. Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, S10 1RX, United Kingdom.
2. Oncology and Clinical Research, University of Leeds, Leeds, LS2 9JT, United Kingdom.
3. Department of Chemistry, University of Sheffield, Brook Hill, Sheffield S3 7HF, United Kingdom.
4. Department of Computer Science, University of York, York, YO10 5GH, United Kingdom.
5. Medical AMRC, University of Sheffield, Factory of the Future, Catcliffe, Rotherham, S60 5TZ, United Kingdom.
*These authors contributed equally to this work.

Citation:
Patel P, Alghamdi A, Shaw G, Legge C, Glover M, Freeman D, Hodgetts H, Wilson E, Howard F, Staniland S, Kennerley AJ, Wood D, Moorehead R, Hadfield C, Rominiyi O, Griffin J, Collis SJ, Hyde S, Crossley M, Paley M, Muthana M. Development of a Personalised Device for Systemic Magnetic Drug Targeting to Brain Tumours. Nanotheranostics 2023; 7(1):102-116. doi:10.7150/ntno.76559. https://www.ntno.org/v07p0102.htm
Other styles

File import instruction

Abstract

Graphic abstract

Delivering therapies to deeply seated brain tumours (BT) is a major clinical challenge. Magnetic drug targeting (MDT) could overcome this by rapidly transporting magnetised drugs directly into BT. We have developed a magnetic device for application in murine BT models using an array of neodymium magnets with a combined strength of 0.7T. In a closed fluidic system, the magnetic device trapped magnetic nanoparticles (MNP) up to distances of 0.8cm. In mice, the magnetic device guided intravenously administered MNP (<50nm) from the circulation into the brain where they localised within mouse BT. Furthermore, MDT of magnetised Temozolomide (TMZmag+) significantly reduced tumour growth and extended mouse survival to 48 days compared to the other treatment groups. Using the same principles, we built a proof of principle scalable magnetic device for human use with a strength of 1.1T. This magnetic device demonstrated trapping of MNP undergoing flow at distances up to 5cm. MDT using our magnetic device provides an opportunity for targeted delivery of magnetised drugs to human BT.

Keywords: Magnetic Nano Particles, Brain Tumours, Magnetic Drug Targeting, Murine Models


Citation styles

APA
Patel, P., Alghamdi, A., Shaw, G., Legge, C., Glover, M., Freeman, D., Hodgetts, H., Wilson, E., Howard, F., Staniland, S., Kennerley, A.J., Wood, D., Moorehead, R., Hadfield, C., Rominiyi, O., Griffin, J., Collis, S.J., Hyde, S., Crossley, M., Paley, M., Muthana, M. (2023). Development of a Personalised Device for Systemic Magnetic Drug Targeting to Brain Tumours. Nanotheranostics, 7(1), 102-116. https://doi.org/10.7150/ntno.76559.

ACS
Patel, P.; Alghamdi, A.; Shaw, G.; Legge, C.; Glover, M.; Freeman, D.; Hodgetts, H.; Wilson, E.; Howard, F.; Staniland, S.; Kennerley, A.J.; Wood, D.; Moorehead, R.; Hadfield, C.; Rominiyi, O.; Griffin, J.; Collis, S.J.; Hyde, S.; Crossley, M.; Paley, M.; Muthana, M. Development of a Personalised Device for Systemic Magnetic Drug Targeting to Brain Tumours. Nanotheranostics 2023, 7 (1), 102-116. DOI: 10.7150/ntno.76559.

NLM
Patel P, Alghamdi A, Shaw G, Legge C, Glover M, Freeman D, Hodgetts H, Wilson E, Howard F, Staniland S, Kennerley AJ, Wood D, Moorehead R, Hadfield C, Rominiyi O, Griffin J, Collis SJ, Hyde S, Crossley M, Paley M, Muthana M. Development of a Personalised Device for Systemic Magnetic Drug Targeting to Brain Tumours. Nanotheranostics 2023; 7(1):102-116. doi:10.7150/ntno.76559. https://www.ntno.org/v07p0102.htm

CSE
Patel P, Alghamdi A, Shaw G, Legge C, Glover M, Freeman D, Hodgetts H, Wilson E, Howard F, Staniland S, Kennerley AJ, Wood D, Moorehead R, Hadfield C, Rominiyi O, Griffin J, Collis SJ, Hyde S, Crossley M, Paley M, Muthana M. 2023. Development of a Personalised Device for Systemic Magnetic Drug Targeting to Brain Tumours. Nanotheranostics. 7(1):102-116.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image